Novartis’ Cosentyx and Celgene’s Otezla aren’t just battling it out in the psoriasis arena. As of early this year, they’re competing in psoriatic arthritis, too—and each drugmaker made its case this week with new data in that disease.
Celgene’s Otezla is picking up steam in the U.K. Shortly after winning NICE support in severe psoriasis, it now boasts an initial backing in psoriatic arthritis--and the fact that it's a pill made all the difference.
With her poolside reporting assignment at the Olympics in Rio behind her, Olympic swimmer and 12-time medalist Dara Torres is turning her attention to another event: Celgene’s “Show More of You” campaign.